Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE)
04/30/2003 to 01/31/2009
The SCORE Study’s scientific and regulatory objectives were to compare the efficacy and safety of standard care with intravitreal injection(s) of triamcinolone acetonide (4 mg or 1 mg) to treat macular edema associated with CRVO and BRVO.
Participants with macular edema (swelling of the central part of the retina) associated with central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO) who are 18 years of age or older and are willing to provide consent were eligible for the SCORE Study.
Eighty-four clinical centers across the continental U.S.
Data Analysis and Reporting
Independent Data and Safety Monitoring Board Services
Meeting Coordination and Support
Site Selection and Contracting
Statistical Leadership and Project Management
Study Design/Protocol Development
Training and Certification
Web-based Data Collection and Reporting Systems